Commercialisation Executive Faculty of Medicine

Conor Simpson is a Commercialisation Executive within Imperial College London’s Faculty of Medicine, working at the interface of academia and industry to assess, protect and commercialise innovations in medical devices, diagnostics, AI for healthcare and pharmaceuticals. His role supports Imperial’s ambition to convert cutting-edge clinical research into real-world impact.

Prior to joining Imperial, Conor served as a Business Developer at Leiden University Medical Centre’s Technology Transfer Office, managing a medical-technology portfolio and negotiating licenses and spin-out agreements. He holds an MSc in Bio-Pharmaceutical Sciences & Business Studies from Leiden University and a BSc (Hons) in Pharmacology from University of Glasgow.

Conor's portfolio

Discover all technologies

Complement Factor H Knock Out Mouse Model

Mouse model mimics AMD pathology, enabling preclinical testing of gene therapies targeting complement factor H and related inflammatory diseases.

Charcot-Marie Tooth Disease model

Transgenic mouse model mimics CMT1A pathology, enabling gene therapy testing for inherited neuropathies and autoimmune neurological disorders.

The Benzodiazepine withdrawal symptom questionnaire (BWSQ)

A well-established, validated and widely-used self-assessment scoring system used in a number of clinical trials involving benzodiazepines.

Functionalised biopolymer materials for extracellular vesicle isolation and engineering

EV isolation and engineering methods for scalable manufacturing and advanced therapeutic, diagnostic, and medical applications.

A real-time fluorescence probe for Heme Oxygenase activity

HO-1 probe compositions designed for rapid, accessible readouts of cellular protection in cardiovascular and hematologic conditions.

PROPHSY: Proteome in Pulmonary Hypertension Assay Score

A model score calculated from plasma protein levels for the diagnosis, prognosis, and treatment optimisation of Pulmonary Arterial Hypertension.

Portfolio of human colorectal adenocarcinomas

Six diverse colorectal cancer cell lines enable research into tumour biology, differentiation, and integrin expression for drug development.